NSE · Healthcare · Biotechnology
EPS came in at 2.11 against a street estimate of 1.80 — a beat of 17.2%.
with an average price target of ₹905.12.
| Document | Date |
|---|---|
| Quarterly results · Q1 FY27 ANTHEM BIOSCIENCES LIMITED – Q1FY27 RESULTS SUMMARY HEADLINE NUMBERS • Revenue from Operations: ₹4,182 Mn in Q1FY27 - Down 22.6% year-on-year (₹5, | 2026-07-21 |
| Investor presentation · Q1 FY27 ANTHEM BIOSCIENCES LIMITED – Q1FY27 SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Q1FY27 Revenue from Operations: ₹4,182 Mn (down 22.6% YoY f | 2026-07-21 |
| Investor presentation | 2026-07-21 |
| Quarterly results | 2026-07-02 |
| Annual report FY2026 ANTHEM BIOSCIENCES LIMITED – ANNUAL REPORT FY 2025-26 SUMMARY HEADLINE NUMBERS • Revenue from Operations: ₹21,243 Million (15% growth YoY) • EBITDA: | 2026-06-30 |
| Q4 FY26 earnings call ANTHEM BIOSCIENCES LIMITED – Q4 & FY26 EARNINGS SUMMARY HEADLINE NUMBERS • Full Year FY26 Consolidated Revenue: Rs. 2,124 crores (18% YoY growth) • | 2026-05-22 |
| Quarterly results · Q4 FY26 ANTHEM BIOSCIENCES LIMITED – FINANCIAL SUMMARY HEADLINE NUMBERS • FY2026 Revenue from Operations: INR 20,893.12 million (vs FY2025: INR 18,406.49 mi | 2026-05-19 |
| Investor presentation ANTHEM BIOSCIENCES LIMITED – INVESTOR SUMMARY Earnings Presentation | May 19, 2026 --- HEADLINE NUMBERS • Q4FY26 Revenue: ₹6,109 Mn (+26.4% YoY, +4 | 2026-05-19 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹2 / share ex-date Jun 25, 2026 · record Jun 26, 2026 | 2026-06-25 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Anthem Biosciences Ltd — free to start.
Google PlayApp StoreData updated 2026-09-18.